{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:38:08Z","timestamp":1784806688130,"version":"3.55.0"},"reference-count":27,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psoriasis and Psoriatic Arthritis\u00ae"],"published-print":{"date-parts":[[2025,10]]},"abstract":"\n Background<\/jats:title>\n Limited literature exists on the mortality burden of generalized pustular psoriasis (GPP) in the US.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare all-cause mortality among patients with GPP with matched populations of patients with plaque psoriasis (PsO) and the general population in the US.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n An observational study was conducted using US claims data collected between January 1, 2016 and December 31, 2019. All-cause mortality was evaluated at 365\u00a0days post-index and at maximum follow-up in the following cohorts:\n GPP-only<\/jats:italic>\n ,\n Plaque-PsO-only<\/jats:italic>\n ,\n GPP + PsO<\/jats:italic>\n ,\n All-GPP<\/jats:italic>\n , and\n general population<\/jats:italic>\n . Propensity score matching was used to balance covariates between cohorts. The index date was the first medical claim for GPP (ICD-10 code L40.1) or PsO (L40.0), and a randomly selected date per year for individuals in the\n general population<\/jats:italic>\n cohort.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n 1246 patients were included in\n GPP-only<\/jats:italic>\n , 1384 in\n GPP + PsO<\/jats:italic>\n , 2630 in\n All-GPP<\/jats:italic>\n and 127,540 in\n plaque-PsO-only<\/jats:italic>\n . 19,641,441 individuals were included in\n general population<\/jats:italic>\n . The maximum follow-up ranged from 36.14 to 41.28\u00a0months (3.01-3.44\u00a0years). At 365-day follow-up, mortality risk was significantly higher in the\n All-GPP<\/jats:italic>\n vs the\n general population<\/jats:italic>\n (hazard ratio [HR] 4.93, 95% confidence interval [CI] 2.24-10.88) and\n plaque-PsO-only<\/jats:italic>\n (HR 2.31, 95% CI 1.32-4.04) cohorts. At maximum follow-up, the mortality risk for the\n All-GPP<\/jats:italic>\n cohort was four times higher than the\n general population<\/jats:italic>\n (HR 3.98, 95% CI 2.92-5.43) and 1.5 times higher than the\n plaque-PsO-only<\/jats:italic>\n (HR 1.49, 95% CI 1.20-1.85) cohorts.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Patients with GPP exhibited an elevated mortality risk in comparison to the matched\n plaque-PsO<\/jats:italic>\n and\n general population<\/jats:italic>\n cohorts.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/24755303251344155","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T09:08:46Z","timestamp":1748596126000},"page":"115-123","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis"],"prefix":"10.1177","volume":"10","author":[{"given":"Alice B.","family":"Gottlieb","sequence":"first","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Crooke Kwiatkowski","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Semeco","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhargav","family":"Lakshminarasimhan","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale University, New Haven, CT, USA and Central Connecticut Dermatology, Cromwell, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-5303","authenticated-orcid":false,"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2020.1831315"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2019.1648209"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1951192"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00493-0"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00654-z"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00881-0"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1971.tb14044.x"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18720"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2019.1708193"},{"key":"e_1_3_7_11_2","unstructured":"FDA. FDA approves spesolimab-sbzo the first treatment option for generalized pustular psoriasis flares in adults. https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/new-drug-therapy-approvals-2022. Accessed 8 April 2024."},{"key":"e_1_3_7_12_2","unstructured":"FDA. SPEVIGO (spesolimab-sbzo) is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761244s003lbl.pdf. Accessed 29 April 2024."},{"key":"e_1_3_7_13_2","unstructured":"National Medical Products Administration. Drug Approval Document Release. https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20240311135849130.html (nmpa.gov.cn). Accessed 29 April 2024."},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12863"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12070"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2006.0003"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.008"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14949"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B1300109"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000521288"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2022.2116003"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.14744\/nci.2016.16023"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.4103\/ds.DS-D-24-00070"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14814"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15146"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17097"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/11586900-000000000-00000"}],"container-title":["Journal of Psoriasis and Psoriatic Arthritis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24755303251344155","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24755303251344155","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24755303251344155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:37:52Z","timestamp":1777509472000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24755303251344155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/24755303251344155"],"URL":"https:\/\/doi.org\/10.1177\/24755303251344155","relation":{},"ISSN":["2475-5303","2475-5311"],"issn-type":[{"value":"2475-5303","type":"print"},{"value":"2475-5311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}